Don't ignore these innovative companies.
These businesses should see good times ahead.
This liver-disease specialist might be significantly undervalued.
Both stocks are pretty risky, but one of them more so than the other.
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?
This biotech just got clearance to dive into a deep ocean of a market.
The mid-cap biotech has succeeded where many others failed.
Madrigal has one key advantage over its two huge potential future rivals.
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.15%. Stocks on Friday...